Prosecution Insights
Last updated: November 16, 2026
Application No. 18/674,491

Methods, Systems, Devices And Components for Miniaturized Implantable Gastric Electrical Stimulators and Corresponding Medical Electrical Leads and Electrodes

Non-Final OA §102§103§112
Filed
May 24, 2024
Priority
May 24, 2023 — provisional 63/468,703
Examiner
PORTER, JR, GARY A
Art Unit
3792
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Enterra Medical Inc.
OA Round
1 (Non-Final)
69%
Grant Probability
Favorable
1-2
OA Rounds
94%
With Interview

Examiner Intelligence

Grants 69% — above average
69%
Career Allowance Rate
547 granted / 793 resolved
-1.0% vs TC avg
Strong +25% interview lift
Without
With
+25.0%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
50 currently pending
Career history
872
Total Applications
across all art units

Office Action

§102 §103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Applicant’s election without traverse of Group I, Claims 1-21 in the reply filed on 3/24/2026 is acknowledged. Claims 22-42 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 3/24/2026. Drawings The drawings are objected to under 37 CFR 1.83(a). The drawings must show every feature of the invention specified in the claims. Therefore, the two sets of signals supplied at two separate periods of time wherein the second set of signals have one or more frequencies, pulse widths and amplitudes less that corresponding features of the first set of signals at the first predetermined period of time and the ramping down of one or both sets of signals according to the claim language of Claims 3-5 must be shown or the feature(s) canceled from the claim(s). No new matter should be entered. Fig.9 is currently believed to be the closets figure to the claimed invention but only shows one signal. Corrected drawing sheets in compliance with 37 CFR 1.121(d) are required in reply to the Office action to avoid abandonment of the application. Any amended replacement drawing sheet should include all of the figures appearing on the immediate prior version of the sheet, even if only one figure is being amended. The figure or figure number of an amended drawing should not be labeled as “amended.” If a drawing figure is to be canceled, the appropriate figure must be removed from the replacement sheet, and where necessary, the remaining figures must be renumbered and appropriate changes made to the brief description of the several views of the drawings for consistency. Additional replacement sheets may be necessary to show the renumbering of the remaining figures. Each drawing sheet submitted after the filing date of an application must be labeled in the top margin as either “Replacement Sheet” or “New Sheet” pursuant to 37 CFR 1.121(d). If the changes are not accepted by the examiner, the applicant will be notified and informed of any required corrective action in the next Office action. The objection to the drawings will not be held in abeyance. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 3-7 and 20 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. In regard to Claim 3, Applicant claims “at least one medical lead and one or more electrodes”. It is unclear if the “one or more electrodes” are part of the “at least one stimulation electrode” of Claim1 or if it is different. It is unclear exactly how many electrode are being claimed within the scope of Claim 3. Regarding Claim 5, Applicant claims “generating first electrical stimulation signals” and “generating second electrical stimulation signals”. Applicant then claims “as one or more of the frequencies, pulse widths, and amplitudes of the electrical stimulation signals provided to the patient…”. It is unclear if “the stimulation signals” are referring to the first stimulation signals, the second stimulation signals or both the first and second stimulation signals. Additionally, Claim 5 includes the step of “continue to be successively reduced”. However, there is not a previous mention of successively reducing any stimulation signal so it is unclear what this step is a continuation of. It is further unclear what signal (the first, second or both) is being reduced and when the initial reduction is supposed to take place so that the step of continuing to reduce the signal can occur as claimed. For the purposes of examination, the Claims will be interpreted as a set of stimulation signals that can start at a high value and be ramped down over time (see Fig. 9 for an example of a single signal that can be successively reduced). Appropriate clarification and/or correction is respectfully requested. Claim 6 states “is further configured to provide, on the basis of the frequency, pulse width, and amplitude parameters determined to be associated with reduced or lost efficacy in treating the one or more gastrointestinal disorders of the patient, generating and providing to the patient chronic electrical stimulation signals…”. This limitation is confusing and awkwardly worded. It is also unclear which signals are being referred to with “the frequency, pulse width, and amplitude parameters”. Is it for the first signals only, second signals only or both? Claim 20 sets forth “the method further comprises one or more GPOEM steps, techniques or methods.” Applicant has not firs set forth the full name of the acronym GPOEM. It is also unclear what steps this would include and how said steps would integrate with the already claimed method. The metes and bounds are unclear. Applicant is essentially setting forth the use of a process “without any active, positive steps delimiting how this use is actually practiced” (see MPEP §2173.05(q)). Claims 4 and 7 are rejected due to their dependence on indefinite Claim 3. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claims 1, 8-15 and 17-19 are rejected under 35 U.S.C. 102(a)(1) and 102(a)(2) as being anticipated by Starkebaum et al. (2011/0071589). Regarding Claims 1 and 12, Starkebaum discloses implanting a gastric stimulator 12 having a stimulation module 28 and stimulation electrodes 24, 26 operably connected thereto via leads 18-20 (Fig. 1, 2) for delivering stimulation. Starkebaum further disclose endoscopically implanting portions of the system (such as leads 18, 20) in submucosal layer (par. [0075]). The Examiner notes the language “configured to fit within a first space…”; “configured to be advanced into the first space”; and “configured to be implanted in at least a portion of the second space…” are all intended use limitations. The Examiner notes a recitation of the intended use of the claimed invention must result in a structural difference between the claimed invention and the prior art in order to patentably distinguish the claimed invention from the prior art. If the prior art structure is capable of performing the intended use, then it meets the claim. Starkebaum discloses the claimed structure and therefore the Examiner contends the structure is equally capable of the claimed function. If there are other structural details that make these functions possible, the Examiner suggests positively reciting such structural features to overcome the current interpretation. In regard to Claims 8 and 11, Starkebaum discloses containing the stimulation module 28 in the housing and having one electrode formed on the housing (par. [0075-0076]). With regard to Claims 9 and 19, Starkebaum discloses electrical stimulation electronics and a power source therein ( see elements 28-36 in Fig. 2). Regarding Claim 10, Starkebaum discloses a telemetry interface 34 that wirelessly connects to programmer 14 (Fig. 2). In regard to Claim 13, Starkebaum discloses an embodiment where leads 18, 20 have multiple electrodes 56A-E (Fig. 4B). With regard to Claims 14 and 15, Starkebaum discloses using unipolar, bipolar or multi-polar configurations sing the leads (par. [0063]), wherein bipolar and multi-polar configurations involve at least one electrode being a return electrode. Regarding Claims 17 and 18, Starkebaum discloses anchoring the device with fixation members such as tines (barbs) helical structures, etc. (par. [0079]). Claims 1, 12, 13, 16, 20 and 21 are rejected under 35 U.S.C. 102(a)(1) and 102(a)(2) as being anticipated by Bitton et al. (2008/0065168). Regarding Claims 1 and 20, Bitton discloses an ingestible, temporary stimulator 30 that is configured to be set within an ingestible capsule 34 that can be guided with an endoscope and secured with a tine (hook) (Fig. 1A-C, 4A; par. [0179-0180, 0204]). The device is configured to treat obesity such as by increasing feelings of satiety (par. [0002, 0039]) by applying electrical signals to electrodes 38. The Examiner notes the language “configured to fit within a first space…”; “configured to be advanced into the first space”; and “configured to be implanted in at least a portion of the second space…” are all intended use limitations. The Examiner notes a recitation of the intended use of the claimed invention must result in a structural difference between the claimed invention and the prior art in order to patentably distinguish the claimed invention from the prior art. If the prior art structure is capable of performing the intended use, then it meets the claim. Starkebaum discloses the claimed structure and therefore the Examiner contends the structure is equally capable of the claimed function. If there are other structural details that make these functions possible, the Examiner suggests positively reciting such structural features to overcome the current interpretation. Regarding Claims 12, 13, 16 and 21, Bitton discloses leads 37, 40 are configured to dissolve after a time so that the stimulator can safely pass through the digestive tract after use (par. [0139, 0183]). Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 2-7 are rejected under 35 U.S.C. 103 as being unpatentable over Starkebaum et al. (2011/0071589). Regarding Claims 2 and 4, Starkebaum discloses applying signals to the electrodes, the signals having frequencies ranging from 0.5 Hz to 40 Hz (par. [0011, 0124]); pulse widths ranging from 0.5 milliseconds to 20 milliseconds; and amplitudes from 1 to 25 milliamps (par. [0124]). Starkebaum does not disclose the exact parameters ranges of frequencies between 2-120 Hz; pulse widths of 100 microseconds to 10 milliseconds; or amplitudes between 0.1mA and 20 mA. It would have been obvious to one having ordinary skill in the art before the effective filing date of the claimed inventio to use values in these ranges, since it has been held that where the claimed ranges overlap or lie inside ranges disclosed by the prior art, a prima facie case of obviousness exists. In re Wertheim, 191 USPQ 90. With regard to Claim 3, Starkebaum further discloses applying multiple signals, wherein a first signal in a first time has a greater amplitude than a second signal in a second time (see PW7, PW8 in Fig. 6B). In regard to Claims 5 and 6, Starkebaum discloses using a processor to adjust stimulation parameters to maintain optimal parameters/promote efficacy (par. [0082, 0102, 0105]). These adjustments can be increased values or decreased values. The claims recite intended use limitations of the stimulator and the Examiner notes Starkebaum is capable of performing these adjustments to parameters due to its closed loop nature and programmability. Regarding Claim 7, Starkebaum discloses providing earl satiety to treat obesity (par. [0006]). Conclusion The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. Torgerson (2019/0099601), Dobak (US Patent 7,937,145). Any inquiry concerning this communication or earlier communications from the examiner should be directed to ALLEN PORTER whose telephone number is (571)270-5419. The examiner can normally be reached Mon - Fri 9:00-6:00 EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Carl Layno can be reached at 571-272-4949. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /ALLEN PORTER/Primary Examiner, Art Unit 3796
Read full office action

Prosecution Timeline

May 24, 2024
Application Filed
May 12, 2026
Non-Final Rejection mailed — §102, §103, §112
Nov 09, 2026
Applicant Interview (Telephonic)
Nov 09, 2026
Examiner Interview Summary

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12773560
MEDICAL DEVICE AND METHOD FOR TACHYARRYTHMIA DETECTION
3y 0m to grant Granted Oct 27, 2026
Patent 12745939
MEASUREMENT STATION WITH HANDLE
3y 9m to grant Granted Sep 29, 2026
Patent 12740842
A ROBOTIC SURGICAL INSTRUMENT
2y 8m to grant Granted Sep 22, 2026
Patent 12734361
PHASE ALIGNMENT OF ECAPs
5y 0m to grant Granted Sep 15, 2026
Patent 12734354
Peripheral Nerve Electrode Array
4y 10m to grant Granted Sep 15, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
69%
Grant Probability
94%
With Interview (+25.0%)
Low
PTA Risk
Based on 793 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month